299 related articles for article (PubMed ID: 30268561)
21. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
22. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
[TBL] [Abstract][Full Text] [Related]
24. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R
Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
26. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
[TBL] [Abstract][Full Text] [Related]
27. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Perin RL; Damião AOMC; Flores C; Ludvig JC; Magro DO; Miranda EF; Moraes AC; Nones RB; Teixeira FV; Zeroncio M; Kotze PG
Arq Gastroenterol; 2019; 56(3):312-317. PubMed ID: 31633731
[TBL] [Abstract][Full Text] [Related]
28. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U; Avni-Biron I; Ron Y; Koslowsky B; Waterman M; Daher S; Ungar B; Schwartz D; Zittan E; Openhaim M; Yanai H; Maharshak N; Bar Gil Shitrit A; Naftali T; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Dig Liver Dis; 2019 Jan; 51(1):68-74. PubMed ID: 30172649
[TBL] [Abstract][Full Text] [Related]
30. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
[TBL] [Abstract][Full Text] [Related]
31. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study.
White JR; Din S; Ingram RJM; Foley S; Alam MA; Robinson R; Francis R; Tucker E; Jalal M; Elphick D; Atallah E; Norman A; Amin M; Sajjad A; Heggs N; Meadowcroft S; Moran GW
Scand J Gastroenterol; 2020 Aug; 55(8):907-916. PubMed ID: 32657179
[TBL] [Abstract][Full Text] [Related]
32. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Koliani-Pace JL; Singh S; Luo M; Hirten R; Aniwan S; Kochhar G; Chang S; Lukin D; Gao Y; Bohm M; Swaminath A; Gupta N; Shmidt E; Meserve J; Winters A; Chablaney S; Faleck DM; Yang J; Huang Z; Boland BS; Shashi P; Weiss A; Hudesman D; Varma S; Fischer M; Sultan K; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Siegel CA; Dulai PS
Inflamm Bowel Dis; 2019 Oct; 25(11):1854-1861. PubMed ID: 31050734
[TBL] [Abstract][Full Text] [Related]
33. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
[TBL] [Abstract][Full Text] [Related]
34. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
35. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
[TBL] [Abstract][Full Text] [Related]
37. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
[TBL] [Abstract][Full Text] [Related]
38. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
39. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
40. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
Card T; Ungaro R; Bhayat F; Blake A; Hantsbarger G; Travis S
Aliment Pharmacol Ther; 2020 Jan; 51(1):149-157. PubMed ID: 31747086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
